IPL & Laser Therapy: What to Expect

Intense pulsed light (IPL) and vascular lasers are used for persistent facial redness and visible vessels in rosacea when topicals are not enough. Devices differ by wavelength — roughly green (about 532 nm), yellow-orange (about 585–595 nm), near-infrared (1064 nm), or broadband IPL with filters. Published trials report meaningful average clearance of telangiectasia and erythema for many people, usually after a short series of sessions. Light therapy is not a cure; maintenance and trigger care still matter.

Laser and IPL types used in rosacea (wavelengths & “colors”)

Wavelength matters because hemoglobin in vessels absorbs certain bands of light. Clinics may describe devices by brand, but research papers usually report nanometers (nm). Everyday “color” labels map roughly like this:

Example study: 532 nm KTP vs 595 nm PDL (split-face, n = 15)

Uebelhoer and colleagues treated 15 people in a split-face comparison: 595 nm PDL on one side and pulsed 532 nm KTP on the other, with assessment 3 weeks after three sessions (Dermatologic Surgery, 2007).

• Average clearing after the first treatment: about 62% (KTP) vs 49% (PDL).
• Average clearing 3 weeks after the third treatment: about 85% (KTP) vs 75% (PDL).
• Both sides improved; the authors reported KTP as at least as effective, and often more effective, for telangiectasia and diffuse redness in that cohort — with more short-term swelling/erythema noted on the KTP side for some patients.

Example study: modern 532 nm KTP vs 595 nm PDL (n = 45)

Nguyen and colleagues ran a prospective, controlled, evaluator-blinded study of 45 adults (mean age 51) allocated 2:1 to variable-sequenced large-spot 532 nm KTP or 595 nm PDL, with 1–3 sessions 6–8 weeks apart and follow-up about 6 weeks after treatment (Journal of Cosmetic Dermatology, 2024). Erythema fell significantly in both arms; blinded clinical ratings showed high improvement without a clear efficacy gap between devices. Mean pain was lower with KTP (about 2.5/10) than PDL (about 4.1/10). Relevant purpura was reported only in the PDL group in that study.

Example study: PDL vs several IPL filter setups (n = 60)

Gao and colleagues randomized 60 people with erythematotelangiectatic rosacea into four light groups for four sessions at 4-week intervals (Lasers in Medical Science, 2024; ClinicalTrials.gov NCT05360251):

• PDL at 595 nm.
• Delicate Pulse Light (DPL) IPL band 500–600 nm.
• IPL with a 590 nm filter (590–1200 nm).
• IPL with a dual “vascular” filter (530–650 nm and 900–1200 nm).

Within each group, clinical symptom scores, VISIA red-area scores, and RosaQoL scores improved significantly versus baseline. Between-group differences in efficacy were not statistically significant — non-purpuragenic PDL and these IPL configurations performed similarly overall in that trial, with good tolerability (blister risk was higher in the dual vascular IPL arm).

What meta-analyses say about IPL vs PDL

A 2024 systematic review and meta-analysis comparing IPL and PDL for rosacea pooled four studies (141 participants total). Rates of achieving more than 50% clearance did not differ significantly. Achieving more than 75% clearance favored IPL in that pooled analysis, while pain scores favored PDL on average. Erythema-index change was similar between modalities. Authors concluded both can work; choice may hinge on clearance goals versus comfort — and noted that direct comparative literature is still limited.

An earlier systematic review with meta-analysis of light-based therapies (International Journal of Dermatology, 2021) found that among devices, PDL has the most robust evidence base, while pooled comparisons did not prove PDL superior to other light-based options such as Nd:YAG or IPL for the outcomes studied. Overall certainty of recommendations for light devices in rosacea remains low-to-moderate in evidence reviews — including Cochrane phenotype-based summaries that support laser/IPL mainly for erythema and telangiectasia with cautious GRADE ratings.

Quality-of-life example (595 nm PDL, n = 20)

A prospective clinic series of 20 people treated with 595 nm PDL over three sessions reported mean Dermatology Life Quality Index (DLQI) scores falling from 17.3 before treatment to 4.3 afterward (Journal of Clinical and Aesthetic Dermatology, 2013) — a large average improvement in how much rosacea affected daily life in that small cohort. Individual results still vary widely.

What a typical course looks like

• Often several sessions spaced about 4–8 weeks apart (study protocols vary).
• Temporary redness, swelling, or (with some PDL settings) purpura can occur; downtime depends on device and aggressiveness.
• Darker skin tones need carefully chosen wavelengths and fluences because melanin also absorbs light — ask who will treat you and how settings are adjusted.
• Topicals for bumps, barrier care, SPF, and trigger management usually continue; light therapy is one tool, not a full replacement for medical care.

For daily barrier support around procedures, see a rosacea-friendly skincare routine. For how medical approaches differ when bumps look like acne, see rosacea vs acne treatment.

Questions to ask before booking

• Which device and wavelength (nm) will you use — PDL, KTP, Nd:YAG, or IPL with which filter?
• How many sessions do you expect, and what clearance rate do you quote from your own outcomes?
• What downtime and side effects are typical for my skin type?
• Who operates the device, and how are settings chosen for darker skin or ocular rosacea history?